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) administered once weekly followed by a 2-week rest period; each cycle was repeated every 8 weeks.
Results: A total of 14 patients were identified. The disease control rate was 35.7%. The median progression-free survival was 1.6 months (95% confidence interval [CI], 1.3~2.0 months), and the median overall survival was 6.3 months (95% CI, 4.7~7.9 months). No patient died from treatment-related causes. The most common severe adverse event associated with bolus 5-FU and lleucovorin was neutropenia, which occurred in 21.4% of patients. Conclusions: Bolus 5-FU and l-leucovorin treatment might be useful for oral FU-resistant GC. We are planning a multi-center prospective phase II trial to evaluate the efficacy and safety of bolus 5-FU and l-leucovorin treatment for pre-treated unresectable or recurrent GC to confirm the results of this limited, retrospective study.
Key Words: Stomach neoplasms; Drug therapy; 5-fluorouracil; Leucovorin whereas the RAINBOW 6, 7 and REGARD 8 trials demonstrated that ramucirumab, which is a humanized antibody against vascular endothelial growth factor, prolonged the OS of patients with GC who were treated both with and without paclitaxel. After the development of resistance to first-line chemotherapy, docetaxel or irinotecan as second-line chemotherapy can prolong OS as compared with best supportive care alone. 9 However, there is a non-negligible number of patients with GC resistant to all of these chemotherapy regimens who require further chemotherapy.
The International Organization for Standardization-5FU10 study 10 reported that the efficacy of weekly bolus 5-FU and lleucovorin therapy was not inferior to that of S-1 monotherapy, which was the standard first-line chemotherapy for unresectable advanced GC in Japan during that time. There are two known mechanisms underlying the anti-cancer effects of 5-FU. 11, 12 One is the inhibition of DNA synthesis through the inhibition of Materials and Methods
Patients
We retrospectively analyzed the medical records of all patients with unresectable or recurrent GC and enrolled patients treated with bolus 5-FU and l-leucovorin after failure of S-1 or capecitabine between January 2010 and December 2015 at Hokkaido University Hospital.
Study design and approval
This study was a retrospective cohort single-center analysis to evaluate the efficacy and safety of bolus 5-FU and l-leucovorin against oral fluoropyrimidine-resistant unresectable GC. The study protocol was approved by the Institutional Review Board of Hokkaido University Hospital and conducted in accordance with the tenants of the Declaration of Helsinki.
Treatment
The bolus 5-FU and l-leucovorin regimen consisted of intra- 
Statistical analysis
PFS was calculated from the first day of treatment to the time of disease progression or last follow-up. OS was calculated from the first day of the treatment to the time of death or last followup. OS and PFS were calculated using the Kaplan-Meier method.
Statistical analyses were performed using IBM SPSS Statistics ver. 
Results

Patient characteristics
We identified 14 patients treated with bolus 5-FU and lleucovorin at Hokkaido University Hospital between January 2010
and December 2015. Almost all patients had previously received more than three anti-GC chemotherapy regimens. Patient characteristics are listed in Table 1 and 2. The median number of rapid infusions of 5-FU and l-leucovorin was 7 (range, 5~54) and the median relative dose intensity of 5-FU was 97%.
Efficacy
The objective response rate was 0% and the disease control rate was 35.7% (5 of 14 patients achieved stable disease). The median PFS was 1.6 months (95% confidence interval [CI], 1.3~2.0 months) (Fig. 1 ) and the median OS was 6.3 months (95% CI, 4.7~7.9 months) (Fig. 2) . Table 3 .
Effect of 5-FU and L-Leucovorin
Discussion
Bolus 5-FU and l-leucovorin is reportedly not inferior to S-1 monotherapy for treatment of unresectable GC or to con- In our study, 5 of 14 patients achieved stable disease after this treatment and 6 patients survived for more than 6 months after the first treatment. Each of these patients had received S-1 or capecitabine for GC and almost all were heavily treated in the past, which was thought to have prolonged their survival.
Almost all of the patients' performance status was scored as 1 or 2; there was 1 patient whose performance status was scored as 3. Her poor performance status was due to bone-marrow invasion verified by bone-marrow puncture after heavy treatment;
however, she strongly desired to be treated with another regimen.
Therefore, we administered bolus 5-FU and l-leucovorin after obtaining informed consent.
In the REGARD 8 trial, the PFS and OS of the placebo group of patients with unresectable GC were 1.3 months and 3.8 months, respectively, while the GRANITE-1 trial 13 reported PFS and OS of the placebo group were 1.4 months and 4.3 months, respectively. The outcomes of the placebo groups of patients with unresectable GC were extremely poor and their PFS and OS were shorter than in our study.
The results of the present study indicate that bolus 5-FU and l-leucovorin treatment might be a viable treatment option for pre-treated unresectable GC. However, this study was limited by its small sample size, retrospective analysis, and being conducted Values are presented as number (%). *Classification according to the NCI-CTCAE (National Cancer institute-Common Terminology Criteria for Adverse Events).
Hospital Medical Information Network Clinical Trial Registry and
we are now recruiting patients from multiple institutions associated with the Hokkaido Gastric Cancer Study Group. The results of the present study will be further evaluated by this subsequent prospective trial.
